Skip to Content

Laquinimod Approval Status

Laquinimod is an oral, CNS-active immunomodulator in development for the treatment of relapsing-remitting multiple sclerosis (RRMS), primary-progressive multiple sclerosis (PPMS) and Huntington disease.

Development Status and FDA Approval Process for laquinimod

DateArticle
Jan  4, 2016Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials
Jun 25, 2015Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide